An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery

VXM01 in combination with avelumab in n=30 patients with progressive glioblastoma following standard treatment, with or without second surgery

开始日期2018-11-21

申办/合作机构

Vaximm AG

[+2]

NCT02718443 / Completed临床1期

VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma to Examine Safety, Tolerability, Immune and Biomarker Response to the Investigational VEGFR-2 DNA Vaccine VXM01

VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01

开始日期2016-05-01

申办/合作机构

Vaximm AG

NCT02718430 / Completed临床1期

VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis Under Second or Third Line Therapy to Examine Safety, Efficacy, and Immune Biomarkers After Treatment With VXM01

Phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy to examine safety, efficacy, and immune biomarkers after treatment with VXM01

开始日期2016-02-01

申办/合作机构

Vaximm AG

100 项与 VEGFR2 peptide vaccine(Merck Serono SA) 相关的临床结果

登录后查看更多信息

100 项与 VEGFR2 peptide vaccine(Merck Serono SA) 相关的转化医学

登录后查看更多信息

100 项与 VEGFR2 peptide vaccine(Merck Serono SA) 相关的专利（医药）

登录后查看更多信息

122

项与 VEGFR2 peptide vaccine(Merck Serono SA) 相关的文献（医药）

2024-05-31·BMB Reports

MMPP is a novel VEGFR2 inhibitor that suppresses angiogenesis via VEGFR2/AKT/ERK/NF-κB pathway

作者: Hong, Jin Tae ; Kim, Na-Yeon ; Lee, Hee Pom ; Park, Hyo-Min ; Yoon, Do-Young ; Park, Jae-Young ; Kim, Uijin ; Shin, Ha Youn

Many types of cancer are associated with excessive angiogenesis. Anti-angiogenic treatment is an effective strategy for treating solid cancers. This study aimed to demonstrate the inhibitory effects of (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) phenol (MMPP) in VEGFA-induced angiogenesis. The results indicated that MMPP effectively suppressed various angiogenic processes, such as cell migration, invasion, tube formation, and sprouting of new vessels in human umbilical vein endothelial cells (HUVECs) and mouse aortic ring. The inhibitory mechanism of MMPP on angiogenesis involves targeting VEGFR2. MMPP showed high binding affinity for the VEGFR2 ATP-binding domain. Additionally, MMPP improved VEGFR2 thermal stability and inhibited VEGFR2 kinase activity, suppressing the downstream VEGFR2/AKT/ERK pathway. MMPP attenuated the activation and nuclear translocation of NF-κB, and it downregulated NF-κB target genes such as VEGFA, VEGFR2, MMP2, and MMP9. Furthermore, conditioned medium from MMPP-treated breast cancer cells effectively inhibited angiogenesis in endothelial cells. These results suggested that MMPP had great promise as a novel VEGFR2 inhibitor with potent anti-angiogenic properties for cancer treatment via VEGFR2/AKT/ERK/NF-κB signaling pathway. [BMB Reports 2024; 57(5): 244-249].

2024-04-01·Heliyon

Evaluation of the efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant and conversion therapy for advanced gastric cancer: A study protocol of prospective single-center, randomized controlled and open label clinical trial (RNPLS-01)

Article

作者: Li, Haolin ; Yang, Jianjun ; Wang, Juan ; Xu, Guanghui ; Huo, Huade ; Wang, Shu ; Wang, Haoyuan ; Ji, Gang ; Ma, Yuxuan ; Liu, Shushang ; Li, Mengbin ; Wang, Yuhao ; Peng, Chaosheng ; Zhao, Yan

ObjectiveRamucirumab is a VEGFR2 antagonist. The aim of this trial is to evaluate the efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin and S-1 in neoadjuvant and conversion therapy for advanced gastric cancer.Methodsand analysis: This study is a prospective single-center, randomized controlled and open label clinical study, enrolling a total of 140 patients with advanced gastric cancer distributed across two distinct cohorts (Cohort A n = 70; Cohort B n = 70). The central focus of the study lies in evaluating the pathological complete response (pCR) of the cancer post-neoadjuvant or conversion therapy. Secondary endpoints encompass the assessment of the R0 resection rate subsequent to the aforementioned therapies, the occurrence of adverse events (AE), progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), the total response rate and its duration, the disease control rate (DCR), and the duration of overall response (DOR).EthicsEthics approval has been obtained from the Ethics Committee at the First Affiliated Hospital (Xijing Hospital) of Air force Military Medical University (KY20232220-F-1).Trial registrationThis trial has been registered at the ClinicalTrials.gov: NCT06169410 (registration date: December 5, 2023).

2024-04-01·International Immunopharmacology

CPD-002, a novel VEGFR2 inhibitor, relieves rheumatoid arthritis by reducing angiogenesis through the suppression of the VEGFR2/PI3K/AKT signaling pathway

Article

作者: Zhang, Man-Yu ; Jiang, Fei ; Li, Fei-Long ; Zhang, Pei-Pei ; Yang, Yu-Chen ; Wang, Meng-Qing ; Xie, Ya-Wen ; Gu, Sheng-Long ; Zhou, Meng-Yuan ; Huang, Yan ; Li, Rong ; Liu, Xue-Song

Synovial angiogenesis is a key player in the development of rheumatoid arthritis (RA), and anti-angiogenic therapy is considered a promising approach for treating RA. CPD-002 has demonstrated efficacy in suppressing tumor angiogenesis as a VEGFR2 inhibitor, but its specific impacts on RA synovial angiogenesis and possible anti-RA effects need further study. We examined the influences of CPD-002 on the migration and invasion of human umbilical vein endothelial cells (HUVECs) and its impacts on HUVECs' tube formation and vessel sprouting ex vivo. The therapeutic potential of CPD-002 in adjuvant-induced arthritis (AIA) rats and its suppression of synovial angiogenesis were examined. The involvement of the VEGFR2/PI3K/AKT pathway was assessed both in HUVECs and AIA rat synovium. Here, CPD-002 inhibited the migration and invasion of VEGF-stimulated HUVECs, decreased their chemotactic response to RA fibroblast-like synoviocyte-released chemoattractants, and exhibited anti-angiogenic effects in vitro and ex vivo. CPD-002's targeting of VEGFR2 was confirmed with molecular docking and cellular thermal shift assays, supported by the abolishment of CPD-002's effects upon using VEGFR2 siRNA. CPD-002 relieved paw swelling, arthritis index, joint damage, and synovial angiogenesis, indicating its anti-arthritic and anti-angiogenic effects in AIA rats. Moreover, the anti-inflammatory effects in vivo and in vitro of CPD-002 contributed to its anti-angiogenic effects. Mechanistically, CPD-002 hindered the activation of VEGFR2/PI3K/AKT pathway in VEGF-induced HUVECs and AIA rat synovium, as evidenced by reduced p-VEGFR2, p-PI3K, and p-AKT protein levels alongside elevated PTEN protein levels. Totally, CPD-002 showed anti-rheumatoid effects via attenuating angiogenesis through the inhibition of the VEGFR2/PI3K/AKT pathway.

项与 VEGFR2 peptide vaccine(Merck Serono SA) 相关的新闻（医药）

2023-07-12

·FierceBiotech

South Korean biotech group spies US SPAC as route to Nasdaq

The plan is to take the holding company onto the Nasdaq under the new name OSR Biosciences in the fourth quarter. OSR Holdings is the latest biotech business to choose a merger with a special purpose acquisition company (SPAC) as a way to hop onto the public markets. Seoul, South Korea-headquartered OSR is a global healthcare holding company with operations including a pair of subsidiaries in South Korea and Switzerland focused on developing drugs for oncology and osteoarthritis. The company also owns a distributor of medical devices for neurovascular and other diseases and last week announced plans to acquire Landmark BioVentures, another Swiss company that operates four oncology- and immunology-focused biotech ventures in France. The latest announcement will see OSR merge with U.S.-based Bellevue Life Sciences Acquisition. The SPAC went public in February with a $60 million IPO and the goal of finding a suitable healthcare-focused company to join forces with. In OSR, it appears to have found the desired target, and the plan is to take the holding company onto the Nasdaq under the new name OSR Biosciences in the fourth quarter of the year. The only clinical-stage candidate in OSR’s portfolio is VXM01, an immunotherapy in phase 1/2 development by the Swiss-German biotech Vaximm for glioblastoma in combination with Merck KGaA’s Bavencio. Vaximm also has therapies targeting the proteins mesothelin, WT1 and PD-L1 in preclinical development. "We are delighted to identify OSR Holdings as our candidate,” Bellevue Life Sciences Acquisition's CEO Kuk Hyoun Hwang said in a postmarket release yesterday. “OSR Holdings represents a timely investment opportunity working on the development of breakthrough therapies for unmet medical needs." While SPAC deals were a hot ticket for biotechs to go public a couple of years ago, the rush cooled in 2022 as the industry hit tough times. Since then, their use has been more sporadic, with some companies testing the SPAC waters again near the year’s end. This spring also saw a trickle of merger announcements, with Anew Medical, enGene and NKGen Biotech all opting for the blank check route to market.

并购IPO

2012-10-02

·BioSpace

VAXIMM Receives Grant to Expand Pipeline of Oral Cancer Vaccines

Basel (Switzerland), Mannheim (Germany), October 2nd, 2012 – VAXIMM AG, a Swiss-German biotech company focusing on cancer vaccines, today announced that its German subsidiary VAXIMM GmbH has been awarded a grant from the leading-edge BioRN cluster “Cell-based and Molecular Medicine” to expand its oral T-cell vaccine technology platform. The cluster competition is a program of Germany´s Federal Ministry of Education and Research (BMBF) to promote top-notch innovation in Germany. VAXIMM’s lead candidate VXM01 is an oral T-cell vaccine, which targets the tumor vasculature. It is currently in Phase I/II clinical evaluation in pancreatic cancer patients at the Heidelberg University Hospital. The funding from the leading-edge cluster program will be used to develop additional cancer vaccines complementary to VXM01, which are based on the same oral T-cell vaccine technology. A second candidate (VXM06), which targets an undisclosed, abundant, tumor-specific antigen, is already in preclinical development. Two further product candidates are at discovery stage. VAXIMM’s oral T-cell vaccine technology has a number of advantages. The platform can easily and rapidly generate new vaccines, including multivalent vaccines. The resulting products combine oral efficacy with safety and excellent tolerability. Moreover, the vaccines do not require a complex manufacturing infrastructure. “We are pleased about the recognition of the potential of our oral T-cell vaccination platform,” said Dr. Heinz Lubenau, General Manager of VAXIMM GmbH. “It allows leveraging our work on VXM01 to add additional products to our promising pipeline.” About VAXIMMs Oral T-cell Vaccine Technology: VAXIMM's oral T-cell vaccine platform is based on an approved, live attenuated bacterial vaccine strain, which has been applied in millions of individuals for prophylactic vaccination, and is safe and well tolerated. To yield its oral T-cell vaccines, this strain is modified to carry the genetic information of a specific target antigen. After oral vaccination with such modified bacteria, patients are mounting a strong specific cellular immune response against the target. So-called killer cells of the immune system are then targeting and destroying the corresponding cancer or cancer-associated cells. As a result, the tumor shrinks, while metastasis formation and growth are inhibited. The scalable platform offers many advantages, such as oral efficacy, good tolerability, and ease and low cost of candidate generation and manufacturing. About VAXIMM: VAXIMM is a privately held, Swiss- and German-based biotech company that is primarily focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Its initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. VXM01 has shown impressive anti-tumor activity in numerous animal studies and commenced human clinical trials in 2011. VAXIMM was formed in 2008 as a joint venture of BB Biotech Ventures and Merck KGaA to develop VXM01. Merck Serono Ventures, Sunstone Capital, and BioMedPartners joined as investors in 2010. VAXIMM GmbH is a fully owned subsidiary of VAXIMM AG, located in Mannheim, Germany. For more information, please see Contact: Dr. Heinz Lubenau Tel.: +49 621 8359 687 10 Email: info@vaximm.com Media Inquiries: akampion Dr. Ludger Wess / Ines-Regina Buth Managing Partners info@akampion.com Tel. +49 40 88 16 59 64 Tel. +49 30 23 63 27 68

疫苗

100 项与 VEGFR2 peptide vaccine(Merck Serono SA) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胶质母细胞瘤	临床2期	法国	Vaximm AG	2018-11-21
胶质母细胞瘤	临床2期	荷兰	Vaximm AG	2018-11-21
胶质母细胞瘤	临床2期	德国	Vaximm AG	2018-11-21
复发性胶质母细胞瘤	临床2期	德国	Merck KGaA	2018-11-21
复发性胶质母细胞瘤	临床2期	德国	Vaximm AG	2018-11-21
转移性结直肠癌	临床2期	德国	Vaximm AG	2016-02-01
胰腺继发性恶性肿瘤	临床2期	德国	Vaximm AG	2011-12-01
胶质瘤	临床2期	-	Merck Serono SA	-
结直肠癌	临床1期	-	Merck Serono SA	-
胰腺癌	临床1期	-	Merck Serono SA	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03750071 (ASCO2020) 人工标引	临床1/2期	胶质母细胞瘤	30	avelumab+VXM01	(製窪獵餘淵繭憲顧衊鬱) = 積簾獵觸憲醖鏇製構繭繭夢糧襯壓餘淵構醖遞 (廠範餘衊壓夢窪網遞願 ) 更多	积极	2020-05-29
ASCO2016	临床1期	胰腺癌	-	VXM01	(壓鏇鏇製願餘壓選廠衊) = Drug-related adverse events preferentially associated with boosting doses of VXM01 were decreases in lymphocyte count (22% vs 0) 糧選夢選網鏇醖簾繭構 (夢壓獵餘願顧簾鹽醖壓 ) 更多	积极	2016-05-20
ASCO2016	临床1期	胰腺癌	-	Placebo		积极	2016-05-20
ASCO2009	临床1期	胰腺癌	18	VEGFR2-epitope peptide	製獵獵製廠夢鬱廠襯衊(獵淵餘製醖構壓壓築廠) = 壓顧積蓋淵網蓋衊衊鹹膚窪廠齋鏇繭夢艱膚選 (遞餘鏇蓋繭鑰蓋網鬱鹹 ) 更多	-	2009-05-20